Lev Shvidel

3.0k total citations
82 papers, 1.7k citations indexed

About

Lev Shvidel is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Lev Shvidel has authored 82 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Genetics, 33 papers in Pathology and Forensic Medicine and 30 papers in Immunology. Recurrent topics in Lev Shvidel's work include Chronic Lymphocytic Leukemia Research (51 papers), Lymphoma Diagnosis and Treatment (32 papers) and Immunodeficiency and Autoimmune Disorders (15 papers). Lev Shvidel is often cited by papers focused on Chronic Lymphocytic Leukemia Research (51 papers), Lymphoma Diagnosis and Treatment (32 papers) and Immunodeficiency and Autoimmune Disorders (15 papers). Lev Shvidel collaborates with scholars based in Israel, United States and Germany. Lev Shvidel's co-authors include Alain Berrébi, Michal Haran, Idit Shachar, Mordechai Shtalrid, Inbal Binsky, Nurit Harpaz, Yael Gore, Osnat Bairey, Shirly Becker-Herman and Tamar Tadmor and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Lev Shvidel

80 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lev Shvidel Israel 23 819 573 475 376 253 82 1.7k
Anne Tierens Norway 29 572 0.7× 659 1.2× 914 1.9× 778 2.1× 504 2.0× 101 2.2k
Ayako Arai Japan 28 578 0.7× 269 0.5× 633 1.3× 955 2.5× 539 2.1× 107 2.1k
Steven C. Goldstein United States 24 647 0.8× 313 0.5× 259 0.5× 620 1.6× 246 1.0× 84 2.0k
Tobias A.W. Holderried Germany 19 1.2k 1.4× 295 0.5× 195 0.4× 549 1.5× 629 2.5× 58 1.9k
Melvin Churchill United States 12 521 0.6× 240 0.4× 147 0.3× 356 0.9× 346 1.4× 21 2.1k
Nobuhiro Tsukada Japan 20 1.2k 1.5× 1.2k 2.1× 458 1.0× 658 1.8× 750 3.0× 140 2.9k
Koiti Inokuchi Japan 28 394 0.5× 687 1.2× 302 0.6× 525 1.4× 740 2.9× 145 2.2k
Beverly W. Baron United States 20 623 0.8× 432 0.8× 436 0.9× 359 1.0× 502 2.0× 55 1.8k
Gisela Orozco United Kingdom 31 1.3k 1.6× 197 0.3× 220 0.5× 264 0.7× 764 3.0× 75 2.6k
C A Alper United States 21 1.1k 1.3× 521 0.9× 386 0.8× 94 0.3× 300 1.2× 40 2.0k

Countries citing papers authored by Lev Shvidel

Since Specialization
Citations

This map shows the geographic impact of Lev Shvidel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lev Shvidel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lev Shvidel more than expected).

Fields of papers citing papers by Lev Shvidel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lev Shvidel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lev Shvidel. The network helps show where Lev Shvidel may publish in the future.

Co-authorship network of co-authors of Lev Shvidel

This figure shows the co-authorship network connecting the top 25 collaborators of Lev Shvidel. A scholar is included among the top collaborators of Lev Shvidel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lev Shvidel. Lev Shvidel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shmuely, Haim, et al.. (2023). All-Cause Mortality and Its Predictors in Haemato-Oncology Patients with Febrile Neutropenia. Journal of Clinical Medicine. 12(17). 5635–5635. 4 indexed citations
2.
Michelis, Regina, Judith Chezar, Tamar Tadmor, et al.. (2021). The Role of Alpha 2 Macroglobulin in IgG-Aggregation and Chronic Activation of the Complement System in Patients With Chronic Lymphocytic Leukemia. Frontiers in Immunology. 11. 603569–603569. 9 indexed citations
3.
Michelis, Regina, Tamar Tadmor, Ariel Aviv, et al.. (2020). Cell-free IgG-aggregates in plasma of patients with chronic lymphocytic leukemia cause chronic activation of the classical complement pathway. PLoS ONE. 15(3). e0230033–e0230033. 2 indexed citations
4.
Joffe, Erel, Neta Goldschmidt, Osnat Bairey, et al.. (2018). Outcomes of second‐line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials. European Journal Of Haematology. 101(3). 399–406. 5 indexed citations
5.
Lewinsky, Hadas, Matthias P. Kramer, Lihi Radomir, et al.. (2018). CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia. Journal of Clinical Investigation. 128(12). 5465–5478. 55 indexed citations
6.
Joffe, Erel, Osnat Bairey, Riva Fineman, et al.. (2017). Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival. Hematological Oncology. 36(1). 128–135. 3 indexed citations
7.
8.
Filanovsky, Kalman, Michal Haran, Andrei Braester, et al.. (2017). Clinical Benefit and Improvement of Mitochondrial Function in Low Risk Myelodysplastic Syndrome Treated By Combination Ultra Coenzyme Q10 and L-Carnitine. Blood. 130. 1704–1704. 2 indexed citations
9.
Gil-Yarom, Naama, Lihi Radomir, Lital Sever, et al.. (2016). CD74 is a novel transcription regulator. Proceedings of the National Academy of Sciences. 114(3). 562–567. 107 indexed citations
10.
Tadmor, Tamar, Lev Shvidel, Ariel Aviv, et al.. (2013). Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis. Cancer. 119(10). 1853–1859. 11 indexed citations
11.
Miron, Talia, Meir Wilchek, Lev Shvidel, Alain Berrébi, & Fabian D. Arditti. (2012). S-allyl derivatives of 6-mercaptopurine are highly potent drugs against human B-CLL through synergism between 6-mercaptopurine and allicin. Leukemia Research. 36(12). 1536–1540. 4 indexed citations
12.
Binsky, Inbal, Frida Lantner, Valentin Grabovsky, et al.. (2010). TAp63 Regulates VLA-4 Expression and Chronic Lymphocytic Leukemia Cell Migration to the Bone Marrow in a CD74-Dependent Manner. The Journal of Immunology. 184(9). 4761–4769. 45 indexed citations
13.
Okun, Eitan, et al.. (2009). Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. Leukemia & lymphoma. 50(4). 625–632. 23 indexed citations
14.
Filanovsky, Kalman, et al.. (2009). The May‐Hegglin anomaly. European Journal Of Haematology. 83(4). 390–390. 1 indexed citations
15.
16.
Shvidel, Lev, et al.. (2006). Vincristine-loaded platelet infusion for treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia: Rethinking old cures. American Journal of Hematology. 81(6). 423–425. 17 indexed citations
17.
Shvidel, Lev, et al.. (2003). Acute basophilic leukaemia: eight unsuspected new cases diagnosed by electron microscopy. British Journal of Haematology. 120(5). 774–781. 13 indexed citations
18.
Shtalrid, Mordechai, et al.. (2002). New sporadic case of congenital dyserythropoietic anemia type III in an aged woman: detailed description of ultrastructural findings. American Journal of Hematology. 70(1). 72–76. 9 indexed citations
19.
Klepfish, Abraham, Ronit Sarid, Mordechai Shtalrid, et al.. (2001). Primary Effusion Lymphoma (PEL) in HIV-Negative Patients - a Distinct Clinical Entity. Leukemia & lymphoma. 41(3-4). 439–443. 67 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anne Tierens Breakdown of academic impact, for papers by Ayako Arai Breakdown of academic impact, for papers by Steven C. Goldstein Breakdown of academic impact, for papers by Tobias A.W. Holderried Breakdown of academic impact, for papers by Melvin Churchill Breakdown of academic impact, for papers by Nobuhiro Tsukada Breakdown of academic impact, for papers by Koiti Inokuchi Breakdown of academic impact, for papers by Beverly W. Baron Breakdown of academic impact, for papers by Gisela Orozco Breakdown of academic impact, for papers by C A Alper
Rankless by CCL
2026